Manoe Janssen

Since July 2015, Manoe Janssen is working as a postdoctoral researcher in the group of Professor Roos Masereeuw at Experimental Pharmacology at Utrecht Institute for Pharmaceutical Sciences. In November 2008 she completed the MSc Molecular Mechanisms of Disease at the Radboud University Nijmegen and started her PhD project at the department of Gastroenterology and Hepatology at Radboudumc. In January 2013 she moved to Leuven in Belgium to perform her postdoctoral project at the Stem Cell Institute. She joined the group of Roos Masereeuw at the department of Pharmacology and Toxicology in Nijmegen in January 2015, and moved with the group to Utrecht in July 2015. During her PhD she received the Young Hepatologist Award from the Dutch Society for Hepatology (NVH) and the IGMD Junior Award from the Institute for Genetic and Metabolic Disease (IGMD). In 2016 she received the Kolff Junior Postdoc Grant from the Dutch Kidney Foundation to continue her research into genetic kidney diseases

Research

As part of the Masereeuw group, Manoe Janssen focusses on understanding pathways that can be pharmacologically triggered to enhance the repair and regeneration of the kidney. She focusses on genetic factors and gene mutations that affect proximal tubule function and the development of human in vitro cell models for drug screening.  She makes use of the unique, patented, human renal cell lines from the Masereeuw group who have a high predictive value for drug and waste product transport and metabolism. She compares cells from heathy controls and patients to understand which pathways in the cell are affected, to search for druggable targets and evaluate phenotypic improvements. As part of an international consortium on the genetic kidney disease cystinosis she is testing different drug compounds as well as CRISPR/Cas9 mediated gene repair to find a new therapy for this disease

Selected publications

  1. Janssen MJ, Arcolino FO, Schoor P, Kok RJ, Mastrobattista E. Gene based therapies for kidney regeneration. European Journal of Pharmacology (2016); In Press.
  2. Janssen MJ, Salomon J, Cnossen WR, Bergmann C, Pfundt R, Drenth JP. Somatic loss of polycystic disease genes contributes to the formation of isolated and polycystic liver cysts. Gut (2015);64(4):688-90.
  3. Janssen MJ, Waanders E, te Morsche RH, Xing R, Dijkman HB, Woudenberg J, et al. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology (2011);141(6):2056-63. e2

More information can be found on her staff page